Chemosensitization of tumors by resveratrol.
Because tumors develop resistance to chemotherapeutic agents, the cancer research community continues to search for effective chemosensitizers. One promising possibility is to use dietary agents that sensitize tumors to the chemotherapeutics. In this review, we discuss that the use of resveratrol can sensitize tumor cells to chemotherapeutic agents. The tumors shown to be sensitized by resveratrol include lung carcinoma, acute myeloid leukemia, promyelocytic leukemia, multiple myeloma, prostate cancer, oral epidermoid carcinoma, and pancreatic cancer. The chemotherapeutic agents include vincristine, adriamycin, paclitaxel, doxorubicin, cisplatin, gefitinib, 5-fluorouracil, velcade, and gemcitabine. The chemosensitization of tumor cells by resveratrol appears to be mediated through its ability to modulate multiple cell-signaling molecules, including drug transporters, cell survival proteins, cell proliferative proteins, and members of the NF-κB and STAT3 signaling pathways. Interestingly, this nutraceutical has also been reported to suppress apoptosis induced by paclitaxel, vincristine, and daunorubicin in some tumor cells. The potential mechanisms underlying this dual effect are discussed. Overall, studies suggest that resveratrol can be used to sensitize tumors to standard cancer chemotherapeutics.
Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA.
Subash C
SC
Gupta
Ramaswamy
R
Kannappan
Simone
S
Reuter
Ji Hye
JH
Kim
Bharat B
BB
Aggarwal
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000378:metabolism; D019008:Drug Resistance, Neoplasm / Q000187:drug effects* / Q000502:physiology; D005638:Fruit; D006801:Humans; D009369:Neoplasms / Q000178:diet therapy / Q000188:drug therapy* / Q000378:metabolism; D000077185:Resveratrol; D013267:Stilbenes / Q000008:administration & dosage* / Q000378:metabolism; D014675:Vegetables
D000972:Antineoplastic Agents, Phytogenic; D013267:Stilbenes; D000077185:Resveratrol
Biomed Pharmacother. 2008 Nov;62(9):622-9
18804944
Oncogene. 2006 Feb 9;25(6):838-48
16247474
Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
11252954
Biochem Biophys Res Commun. 2000 Nov 2;277(3):757-63
11062025
Science. 1996 Nov 1;274(5288):784-7
8864119
Int J Cancer. 2010 Jul 15;127(2):257-68
19908231
Nature. 2007 Apr 12;446(7137):749-57
17429392
Cancer Biol Ther. 2008 Aug;7(8):1305-12
18497562
Mol Nutr Food Res. 2009 Jan;53(1):115-28
19072742
Neurochem Int. 2005 Feb;46(3):205-11
15670636
Cell. 1997 Feb 7;88(3):323-31
9039259
Biochem Biophys Res Commun. 2010 Apr 23;395(1):104-10
20350534
Anticancer Res. 2003 Sep-Oct;23(5A):4039-46
14666716
Oncogene. 2004 Sep 2;23(40):6702-11
15273734
Cancer Res. 1997 Oct 1;57(19):4285-300
9331090
Neurosci Lett. 2001 Apr 13;302(1):41-4
11278107
Clin Cancer Res. 1999 Oct;5(10):2908-17
10537360
J Cell Biochem. 1997 Jun 15;65(4):513-26
9178101
Oncogene. 2002 Oct 31;21(50):7611-8
12400004
Oncogene. 2009 Sep 10;28(36):3221-34
19561642
Biochim Biophys Acta. 2010 Oct-Dec;1799(10-12):775-87
20493977
Cancer Res. 2004 Jul 15;64(14):4849-57
15256455
Nat Cell Biol. 2008 Jun;10(6):723-30
18454140
Nat Rev Drug Discov. 2006 Jun;5(6):493-506
16732220
Nat Rev Cancer. 2002 Nov;2(11):815-25
12415252
Cancer Res. 2008 Jun 1;68(11):4406-15
18519703
Mol Cancer Ther. 2004 Jan;3(1):71-84
14749477
Mol Nutr Food Res. 2010 Nov;54(11):1574-84
20521268
Oncol Rep. 2010 Jan;23(1):279-86
19956893
Neoplasma. 2006;53(5):384-92
17013532
Cancer Lett. 2010 Feb 1;288(1):36-41
19616374
Nat Rev Mol Cell Biol. 2002 Sep;3(9):651-62
12209125
Annu Rev Biochem. 1989;58:137-71
2570548
Blood. 2003 Feb 15;101(4):1535-42
12393476
Arch Mal Coeur Vaiss. 1987 Apr;80 Spec No:17-21
3113393
Blood. 2007 Mar 15;109(6):2293-302
17164350
Biochem Biophys Res Commun. 2005 Feb 18;327(3):866-70
15649425
Cancer Res. 2004 Feb 15;64(4):1452-9
14973069
J Biol Chem. 1986 Nov 25;261(33):15544-9
3782078
Semin Cancer Biol. 1997 Jun;8(3):193-204
9441948
Nat Rev Cancer. 2003 Jan;3(1):46-54
12509766
Ann N Y Acad Sci. 2002 Nov;973:392-5
12485899
Am J Obstet Gynecol. 2006 May;194(5):e23-6
16647892
Invest New Drugs. 2009 Oct;27(5):393-401
18841326
Br J Cancer. 2002 May 6;86(9):1518-23
11986789
Cancer Res. 1991 Dec 15;51(24):6543-9
1660341
Cell. 2000 Jan 7;100(1):57-70
10647931
Anticancer Res. 2004 Sep-Oct;24(5A):2783-840
15517885
Mol Pharmacol. 1992 Jan;41(1):69-75
1346333
Cancer Res. 2004 Jun 15;64(12):4294-301
15205344
Endocrinology. 2001 Jan;142(1):370-80
11145600
Eur J Cancer. 2010 Jul;46(10):1882-91
20223651
Blood. 2004 Apr 15;103(8):3175-84
15070700
Cancer Metastasis Rev. 2010 Sep;29(3):405-34
20737283
J Nat Prod. 2003 Jul;66(7):1022-37
12880330
Cancer Res. 2000 Oct 15;60(20):5659-66
11059757
Cancer Res. 1991 Jul 1;51(13):3345-52
1675932
Cell. 1986 Aug 29;46(5):705-16
3091258
Biochem Pharmacol. 2002 Sep;64(5-6):883-8
12213582
Science. 1997 Jan 10;275(5297):218-20
8985016
Mol Cancer Ther. 2004 Feb;3(2):169-78
14985457
Oncogene. 1994 Jun;9(6):1799-805
8183579
Cell Cycle. 2008 Apr 15;7(8):1020-35
18414053
Biochem Biophys Res Commun. 2004 Mar 12;315(3):771-9
14975768
Nat Rev Mol Cell Biol. 2002 Jun;3(6):401-10
12042762
J Natl Cancer Inst. 1995 Aug 16;87(16):1230-7
7563169
J Cell Biochem. 2010 Jul 1;110(4):893-902
20564188
Clin Pharmacokinet. 1989 Apr;16(4):215-37
2656050
J Cancer Res Clin Oncol. 2000 Apr;126(4):198-204
10782892